Adverse associations of these medications with plasma IL-37 levels can be viewed in the light of evidence indicating obesity as a proinflammatory state and the fact that these medications are usually prescribed to obese diabetic patients as being weight-neutral [54]. This evidence concerns the gene IL37 and obesity due to melanocortin 4 receptor deficiency.